The primary objective of this study is to determine the efficacy of a novel enteral nutrition (EN) protocol (delivering 75% of patient's caloric needs through EN) for induction of remission in patients with active childhood-onset Crohn's disease (CD) and compare it to the standard protocol with exclusive enteral nutrition (EEN). This novel approach allows patients to consume remaining calories (25%) from an antiinflammatory diet for CD (AID-CD). The hypothesis is that no significant difference in the remission rate between the novel EN protocol with partial enteral nutrition (PEN) and standard protocol with EEN will be observed.
Background: Exclusive enteral nutrition (EEN) is a well established method of treatment for inducing remission in childhood-onset Crohn's disease. It involves placing children on a strict diet composed only of a single polymeric formula, as the sole source of nutrition over 6 to 8 weeks. Use of this treatment method results in clinical remission in 50% to 80% of children by week 6-8. Partial enteral nutrition (PEN) would be more acceptable to patients than EEN, and might be an effective treatment for active Crohn's disease. Moreover, there are studies suggesting that PEN may be effective for the induction of remission in pediatric patients with Crohn's disease; however, the level of evidence is still low. Methods: This is a prospective randomized controlled trial, in patients with active childhood-onset Crohn's disease comparing two arms over 6 weeks of therapy. Group 1 (PEN group): will receive 75% of their dietary needs from a polymeric formula (Alicalm, Nutricia) and a limited (25% of dietary needs = 1 meal per day) whole food AID-CD for 6 weeks. Group 2 (EEN group): will receive EEN with Alicalm (Nutricia) for 6 weeks. Patients will be seen at onset and week 1, 3, and 6. This study will evaluate clinical response (a decrease in PCDAI score of ≥12.5 points), clinical remission (PCDAI \<10) and mucosal healing using SES-CD in both groups, as well as the effects of the two nutritional approaches on the patients' nutritional status. Antiinflammatory diet for Crohn's disease (AID-CD) is based on reducing exposure to animal fat, simple carbohydrates and processed food. We removed foods that previous research has shown to induce inflammation and added foods that have been shown to be beneficial in reducing inflammation. Our AID-CD is based on Central European and thus Slovenian local and traditional cuisine.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
PEN group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and 25% of daily dietary needs (1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
EEN group will receive 100% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) for 6 weeks.
University Medical Centre Ljubljana
Ljubljana, Slovenia
RECRUITINGClinical Remission
Clinical Remission (Pediatric Crohn's Disease Activity Index \<10) on an intention to treat principle after 6 weeks of therapy.
Time frame: 6 weeks
Clinical response
\- Clinical response defined as a decrease in Pediatric Crohn's Disease Activity Index score of ≥12.5 points) for children or a drop in HBI of at least 2 points in young adults
Time frame: 6 weeks
Mucosal healing
Mucosal healing using the Simple Endoscopic Score for CD (SES-CD)
Time frame: 6-8 weeks
Change in SES-CD
Change in SES-CD from baseline to 6 weeks
Time frame: At week 0 and 6 -8 weeks following enrollment
Changes in specific blood tests
Changes in specific blood tests such as erythrocyte sedimentation rate (ESR), C reactive protein, hemoglobin, albumin, and platelets from baseline to 6 weeks
Time frame: At the 1, 3 and 6 weeks visits
Changes in stool calprotectin concentrations
Changes in stool calprotectin concentrations (mg/kg) from baseline to 6 weeks
Time frame: At the 3 and 6 weeks visits
Changes in weight-z-scores
Changes in weight-z-scores
Time frame: At the 0 and 6 weeks visits
Changes in ITM -z-scores
Changes in ITM -z-scores
Time frame: At the 0 and 6 weeks visits
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.